Evidence map›Paper›PMID 35369875›Full record

ArticleBMC medical research methodology2022

Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain.

Francisco Javier Rubio, Danilo Alvares, Daniel Redondo-Sanchez, Rafael Marcos-Gragera, María-José Sánchez, Miguel Angel Luque-Fernandez

Open access · goldAbstract read
In one paragraph

Article in BMC medical research methodology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Francisco Javier RubioDepartment of Statistical Science, University College London, London, UK.
Danilo AlvaresDepartment of Statistics, Pontificia Universidad Católica de Chile, Macul, Chile.
Daniel Redondo-SanchezNon-communicable Disease and Cancer Epidemiology Group, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, 18012, Spain.
Rafael Marcos-GrageraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, 28029, Spain.
María-José SánchezNon-communicable Disease and Cancer Epidemiology Group, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, 18012, Spain.
Miguel Angel Luque-FernandezNon-communicable Disease and Cancer Epidemiology Group, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, 18012, Spain. miguel-angel.luque@lshtm.ac.uk.
Instituto de Investigación Biosanitaria de Granada · ESInstitut d'Investigació Biomèdica de Girona · ESPontificia Universidad Católica de Chile · CLUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer survival represents one of the main indicators of interest in cancer epidemiology. However, the survival of cancer patients can be affected by several factors, such as comorbidities, that may interact with the cancer biology. Moreover, it is interesting to understand how different cancer sites and tumour stages are affected by different comorbidities. Identifying the comorbidities that affect cancer survival is thus of interest as it can be used to identify factors driving the survival of cancer patients. This information can also be used to identify vulnerable groups of patients with comorbidities that may lead to worst prognosis of cancer. We address these questions and propose a principled selection and evaluation of the effect of comorbidities on the overall survival of cancer patients. In the first step, we apply a Bayesian variable selection method that can be used to identify the comorbidities that predict overall survival. In the second step, we build a general Bayesian survival model that accounts for time-varying effects. In the third step, we derive several posterior predictive measures to quantify the effect of individual comorbidities on the population overall survival. We present applications to data on lung and colorectal cancers from two Spanish population-based cancer registries. The proposed methodology is implemented with a combination of the R-packages mombf and rstan. We provide the code for reproducibility at https://github.com/migariane/BayesVarImpComorbiCancer .

Indexed as

Colorectal NeoplasmsLungBayes TheoremHumansReproducibility of ResultsSpainBayesian variable selectionCancer survivalComorbiditiesConditional effectsMarginal effects

Identifiers

PMID35369875
PMCPMC8978388
OpenAlexW4225908522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.